Cariprazine and Safinamide: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Safinamide
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed safinamide (Xadago) for Parkinson's along with cariprazine (Vraylar). The concern here is theoretical, meaning it hasn't been directly tested in people, but it's worth knowing about.
Cariprazine is broken down by a liver enzyme called CYP3A4, which also creates its long-acting active forms. Safinamide may nudge that enzyme's activity, and because cariprazine and its active pieces stay in the body a long time, it's hard to predict exactly how the levels would shift. The net effect simply isn't clear. The good news: your care team can watch how you're doing and adjust things as needed. Keep taking both as prescribed and check in with your doctor or pharmacist.
Mechanism: Cariprazine is a CYP3A4 substrate; CYP3A4 both forms and eliminates its active metabolites (DCAR, DDCAR), which have very long half-lives. Safinamide is flagged as a potential CYP3A4 inducer.
- Direction/magnitude: Because the same enzyme both generates and clears the active metabolites, the net PK effect of induction is unpredictable and has not been formally evaluated.
- Evidence: Theoretical; onset unspecified.
- Severity: Major; coadministration is labeled not recommended.
- Management: If used together, monitor clinically for altered efficacy or emergent adverse effects; dose may need to be individualized. Consider an alternative if feasible.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
The concurrent use of cariprazine (a substrate of CYP3A4) with a CYP3A4 inducer is not advised. The generation and clearance of cariprazine's active metabolites depend on CYP3A4. How CYP3A4 inducers influence cariprazine exposure has not been studied, so the overall effect remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
What your care team may do:
- Consider whether these two can be used together or whether an alternative fits better, since the combination is labeled as not recommended.
- Monitor you more closely for either reduced benefit or new side effects, since the net effect on cariprazine levels can't be predicted.
- Adjust and individualize your dose if needed based on how you respond.
What you should do: Keep taking both exactly as prescribed unless told otherwise. Tell your pharmacist or prescriber if you notice changes in your symptoms, mood, movement, or any new side effects.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Cariprazine and Safinamide together?
Combining safinamide with cariprazine is labeled not recommended because safinamide may alter cariprazine's metabolism in an unpredictable way; don't stop either drug on your own, but ask your prescriber or pharmacist whether the pairing is right for you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Cariprazine and Safinamide interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Cariprazine and Safinamide interaction managed?
What your care team may do: Consider whether these two can be used together or whether an alternative fits better, since the combination is labeled as not recommended. Monitor you more closely for either reduced benefit or new side effects, since the net effect on cariprazine levels can't be predicted. Adjust and individualize your dose if needed based on how you respond. What you should do: Keep… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Cariprazine or Safinamide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Safinamide
Keep reading about Cariprazine
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist